



Attorney Docket: 1736/5753

PATENT

TECH CENTER 1600/2900

JUL 14 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DENIS GRAVEL ET AL.
Serial No.: 09/786,639 Group Art Unit: 1654
Filed: JUNE 27, 2001 Examiner: M. Meller
Title: GRF ANALOGS WITH INCREASED BIOLOGICAL POTENCY
INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 CFR §1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a corresponding foreign Search Report citing such documents, together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the


first Office Action on the merits, but before a Final Office Action or Notice of Allowance (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement under 37 CFR §1.97(e). No fee under 37 CFR §1.17(p) is required.

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


Respectfully submitted,

July 11, 2003



J. D. Evans
Registration No. 26,269

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:bmf



FORM PTO-1449

U.S. Department of Commerce
Patent & Trademark OfficeAttorney Docket No.
1736/49753Serial No.
09/786,639

Applicant: Denis GRAVEL, et al.

**INFORMATION DISCLOSURE
STATEMENT***(Use several sheets if necessary)*Filing Date
June 27, 2001

Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA	5112808	05/1992	Coy, et al.			
	AB	4914189	04/1990	Schally, et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

RECEIVED
 JUL 14 2003
 TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	TRANSLATION	
							Yes	No
	AK	91/16923	11/1991	WO				
	AL	96/37514 ✓	11/1996	WO				
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	AQ	William A. MURPHY, et al., "Potent Long-Acting Alkylated Analogs of Growth Hormone-Releasing Factor" Peptide Research, Vol. 1, No. 1, 1998, pages 36-41						
	AR	Search Report						
	AS							

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.